This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

Nimbus can't offload psoriasis drug, rules US judge

( October 14, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Nimbus Therapeutics may not encumber assets associated with a psoriasis drug to block Celgene from assigning its rights following a merger with Bristol-Myers Squibb, a judge ruled. US District Judge Jed S. Rakoff issued an injunction blocking Nimbus from taking any actions that would prohibit Celgene from assigning its assets to a third party. Nimbus is currently suing for a declaration that Bristol-Myers’ purchase of Celgene is anticompetitive....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections